Clinical Trial Update: Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating stem cell transplantation with CAMPATH 1H and less toxic chemotherapy for myelodysplastic disorders and leukemia; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Disorders

Drugs mentioned

• Campath-1H (alemtuzumab)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Myelodysplastic Disorders, Leukemia | Phase 1, Phase 2 | Status: COMPLETED